66 results
POS AM
QNRX
Quoin Pharmaceuticals Ltd
29 Mar 24
Prospectus update (post-effective amendment)
4:11pm
financing will be required to complete the research and development of our therapeutic targets and our other operating requirements, which may … cash bonus may be awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may
424B4
QNRX
Quoin Pharmaceuticals Ltd
6 Mar 24
Prospectus supplement with pricing info
5:07pm
to significant uncertainty. Additional financing will be required to complete the research and development of our therapeutic targets and our other … of our therapeutic targets and our other operating requirements, which may not be available at acceptable terms, if at all. If we are unable to obtain
424B3
QNRX
Quoin Pharmaceuticals Ltd
4 Mar 24
Prospectus supplement
5:27pm
to complete the research and development of our therapeutic targets and our other operating requirements, which may not be available at acceptable … and is subject to significant uncertainty. Additional financing will be required to complete the research and development of our therapeutic targets
424B3
4cywr9a5hukrcw cn5l
9 Nov 23
Prospectus supplement
5:15pm
424B3
8octot
14 Sep 23
Prospectus supplement
4:38pm
8-K
EX-10.1
hr1v50yz euav7x
12 Sep 23
Entry into a Material Definitive Agreement
6:01pm
424B3
9lulbs
3 Aug 23
Prospectus supplement
4:51pm
424B3
mkr294e
9 May 23
Prospectus supplement
4:03pm
10-Q
lxepdr28
9 May 23
Quarterly report
3:03pm
424B3
hhf zbw23c6j6n8rii97
10 Nov 22
Prospectus supplement
12:45pm
424B3
p37sy38kyy3
10 Nov 22
Prospectus supplement
12:43pm
6-K
EX-99.1
4u0tv4btpp29u
10 Nov 22
Current report (foreign)
11:08am
6-K
EX-99.2
vrerl905 1qvt9
10 Nov 22
Current report (foreign)
11:08am
424B3
ldrhtrqd
18 Aug 22
Prospectus supplement
2:56pm
424B3
6uy6lv
18 Aug 22
Prospectus supplement
2:54pm